BioSpace News Archive

HeartFlow, Inc., the leader in revolutionizing precision heart care, announced that the results of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization will be presented as Late Breaking Science at the upcoming annual American Heart Association conference, held November 5-7 virtually and in Chicago, Illinois.

Valbiotis, a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, presents additional positive results from the Phase II HEART clinical study with TOTUM•070 for hypercholesterolemia.

Vico Therapeutics B.V., a neurology-focused genetic medicine company, announced the appointment of Scott Schobel, MD as chief medical officer.

PACT Pharma, Inc. announced that it has entered into an agreement to sell select assets to AmplifyBio, a contract research organization focused on accelerating innovation across pharmaceutical modalities.

RedHill Biopharma Ltd. announced study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill’s novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 1 and twice-daily opaganib2.

Mussel Polymers, Inc. has demonstrated that its proprietary Poly molecule induces the mineralization of dentin, specifically causing the deposition of Amorphous Calcium Phosphate.

Channel Medsystems, Inc. announced that the first procedures in Europe were performed with the Cerene® Cryotherapy Device for the treatment of heavy menstrual bleeding.

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing.

Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States.

Acerus Pharmaceuticals Corporation today announced that it has amended the promissory note (the “ Note ”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders.